Current Status and Future Direction of Multi-targeted Drugs 
in the Era of Personalized Therapy
—Overview of Advances in Multi-targeted Therapy in Non-small Cell Lung Cancer

Abstract

Multi-targeted tyrosine kinase inhibitors (TKIs) play important roles in the treatment of non-small cell lung cancer (NSCLC). Recently, results of several large phase III studies have been published, showing bittersweet efficacy of multi-targeted TKIs. In the era of personalized therapy, optimal use of multi-targeted TKIs is worthy of further investigation. In this review, we summarized current clinical development and future direction of multi-targeted TKIs in NSCLC..

Keywords

• Lung neoplasms
• Multi-targeted tyrosine kinase inhibitor
• Sunitinib
• Sorafenib
• Vandetanib
• Crizotinib